Thelansis’s "Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Pustular Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory skin disorder characterised by widespread sterile neutrophilic pustulation on erythematous skin, distinct from plaque psoriasis in pathophysiology, genetics, and management. Loss-of-function mutations in IL36RN encoding the IL-36 receptor antagonist are the most prevalent genetic driver, with additional mutations in CARD14, AP1S3, and MPO identified in subsets, collectively resulting in unchecked IL-36 pathway hyperactivation and massive neutrophilic skin inflammation. Flares may be triggered by infection, pregnancy, medication withdrawal including systemic corticosteroids, and stress. Patients present acutely with widespread erythema, sheets of coalescing sterile pustules, fever, and systemic inflammatory response, with severe flares complicated by sepsis, hepatic dysfunction, hypoalbuminaemia, and cardiovascular compromise. Diagnosis is clinical and histopathological, supported by elevated inflammatory markers and neutrophilia, with genetic testing informing long-term management. Spesolimab, a first-in-class IL-36 receptor antagonist monoclonal antibody, is the landmark approved therapy for acute GPP flares, delivering rapid pustular clearance; its subcutaneous formulation is additionally approved for maintenance therapy preventing flare recurrence. Imsidolimab, a second IL-36 receptor antagonist with robust Phase III GEMINI trial data, is currently under active FDA regulatory review with a PDUFA date in late 2026, representing a highly anticipated near-term addition to the GPP armamentarium. Prognosis varies with flare severity and genetic background; multidisciplinary dermatological care, trigger avoidance, and patient-centred monitoring are integral to long-term management.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.